Sisaf

SiSaf is a biopharmaceutical company developing RNA therapeutics for cancer and musculoskeletal disorders using its proprietary Bio-Courier technology. The platform combines bioabsorbable silicon with lipids and amino acids to deliver RNA therapeutics, addressing limitations of conventional lipid nanoparticles by enabling particles to be manufactured empty and loaded with RNA at the point of use, eliminating the need for ultra-cold supply chains. SiSaf's pipeline includes miRNA-based treatments for pancreatic cancer, siRNA-based therapies for metastatic cancer, and siRNA therapy for osteopetrosis ADO2, a rare skeletal disease. Founded in 2006 and headquartered in Belfast, United Kingdom, the company has raised approximately $32.6M in Series B funding from investors including Vickers Venture Partners, Croda, Invest Northern Ireland, and Co-Fund NI. SiSaf differentiates itself through its silicon-stabilized hybrid lipid nanoparticle technology enabling local manufacturing and stable supply chain for RNA therapeutics.